Details of the Drug

General Information of Drug (ID: DM6AN32)

Drug Name
Trovafloxacin
Synonyms
TVFX; Trovan; Fluorinated quinolone; Trovafloxacin [INN]; CP 99219; CP99219; CP 99,219; CP-99219;Trovafloxacin (INN); Trovan (TN); Trovan (oral); Turvel (TN); CP-99,219; (1alpha,5alpha,6alpha)-7-(6-Amino-3-azabicyclo[3.1.0]hex-3-yl)-1-(2,4-difluorophenyl)-6-fluoro-4-oxo-1,4-dihydro-1,8-naphthyridine-3-carboxylic acid; 7-((1R,5S)-6-Amino-3-aza-bicyclo[3.1.0]hex-3-yl)-1-(2,4-difluoro-phenyl)-6-fluoro-4-oxo-1,4-dihydro-[1,8]naphthyridine-3-carboxylic acid; 7-[(1R,5S)-6-amino-3-azabicyclo[3.1.0]hexan-3-yl]-1-(2,4-difluorophenyl)-6-fluoro-4-oxo-1,8-naphthyridine-3-carboxylic acid; 7-[(1R,5S,6s)-6-amino-3-azabicyclo[3.1.0]hex-3-yl]-1-(2,4-difluorophenyl)-6-fluoro-4-oxo-1,4-dihydro-1,8-naphthyridine-3-carboxylic acid; 7-[(1r,5s)-6-amino-3-azabicyclo[3.1.0]hex-3-yl]-1-(2,4-difluorophenyl)-6-fluoro-4-oxo-1,4-dihydro-1,8-naphthyridine-3-carboxylic acid
Indication
Disease Entry ICD 11 Status REF
Acute gonococcal cervicitis N.A. Approved [1]
Bacterial infection 1A00-1C4Z Approved [2]
Endomyometritis N.A. Approved [1]
Mycoplasma pneumoniae pneumonia N.A. Approved [1]
Staphylococcal pneumonia N.A. Approved [1]
Urinary tract infection GC08 Approved [1]
Pneumonia caused by chlamydia N.A. Investigative [1]
⏷ Show the Full List of Indication(s)
Therapeutic Class
Antiinfective Agents
Affected Organisms
Enteric bacteria and other eubacteria
ATC Code
J01MA13: Trovafloxacin
J01MA: Fluoroquinolones
J01M: QUINOLONE ANTIBACTERIALS
J01: ANTIBACTERIALS FOR SYSTEMIC USE
J: ANTIINFECTIVES FOR SYSTEMIC USE
J01MA13: Trovafloxacin
J01MA: Fluoroquinolones
J01M: QUINOLONE ANTIBACTERIALS
J01: ANTIBACTERIALS FOR SYSTEMIC USE
J: ANTIINFECTIVES FOR SYSTEMIC USE
Drug Type
Small molecular drug
Structure
3D MOL 2D MOL
#Ro5 Violations (Lipinski): 0 Molecular Weight (mw) 416.4
Logarithm of the Partition Coefficient (xlogp) 0.3
Rotatable Bond Count (rotbonds) 3
Hydrogen Bond Donor Count (hbonddonor) 2
Hydrogen Bond Acceptor Count (hbondacc) 10
ADMET Property
BDDCS Class
Biopharmaceutics Drug Disposition Classification System (BDDCS) Class 3: high solubility and low permeability [3]
Bioavailability
91% of drug becomes completely available to its intended biological destination(s) [4]
Clearance
The drug present in the plasma can be removed from the body at the rate of 1.4 mL/min/kg [5]
Half-life
The concentration or amount of drug in body reduced by one-half in 9.1 - 12.2 hours [5]
Metabolism
The drug is metabolized via the conjugation []
Unbound Fraction
The unbound fraction of drug in plasma is 0.24% [5]
Vd
Fluid volume that would be required to contain the amount of drug present in the body at the same concentration as in the plasma 1.3 L/kg [5]
Chemical Identifiers
Formula
C20H15F3N4O3
IUPAC Name
7-[(1R,5S)-6-amino-3-azabicyclo[3.1.0]hexan-3-yl]-1-(2,4-difluorophenyl)-6-fluoro-4-oxo-1,8-naphthyridine-3-carboxylic acid
Canonical SMILES
C1[C@@H]2[C@@H](C2N)CN1C3=C(C=C4C(=O)C(=CN(C4=N3)C5=C(C=C(C=C5)F)F)C(=O)O)F
InChI
InChI=1S/C20H15F3N4O3/c21-8-1-2-15(13(22)3-8)27-7-12(20(29)30)17(28)9-4-14(23)19(25-18(9)27)26-5-10-11(6-26)16(10)24/h1-4,7,10-11,16H,5-6,24H2,(H,29,30)/t10-,11+,16?
InChIKey
WVPSKSLAZQPAKQ-SOSAQKQKSA-N
Cross-matching ID
PubChem CID
62959
ChEBI ID
CHEBI:9763
CAS Number
147059-72-1
UNII
9F388J00UK
DrugBank ID
DB00685
TTD ID
D03WPA
Repurposed Drugs (RPD) Click to Jump to the Detailed RPD Information of This Drug

Molecular Interaction Atlas of This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Bacterial DNA gyrase (Bact gyrase) TTN6J5F GYRA_STAAU ; GYRB_STAAU Modulator [6]

Drug Off-Target (DOT)
DOT Name DOT ID UniProt ID Interaction REF
Aromatase (CYP19A1) OTZ6XF74 CP19A_HUMAN Gene/Protein Processing [7]
Autophagy protein 5 (ATG5) OT4T5SMS ATG5_HUMAN Gene/Protein Processing [8]
Autophagy-related protein 101 (ATG101) OTG8QUXY ATGA1_HUMAN Gene/Protein Processing [8]
Autophagy-related protein 16-1 (ATG16L1) OTEOYC5D A16L1_HUMAN Gene/Protein Processing [8]
Autophagy-related protein 2 homolog B (ATG2B) OT7FGFJ1 ATG2B_HUMAN Gene/Protein Processing [8]
Autophagy-related protein 9B (ATG9B) OTJMJZW8 ATG9B_HUMAN Gene/Protein Processing [8]
Baculoviral IAP repeat-containing protein 2 (BIRC2) OTFXFREP BIRC2_HUMAN Gene/Protein Processing [9]
Baculoviral IAP repeat-containing protein 3 (BIRC3) OT3E95KB BIRC3_HUMAN Gene/Protein Processing [9]
Beclin 1-associated autophagy-related key regulator (ATG14) OTPZDKI0 BAKOR_HUMAN Gene/Protein Processing [8]
Caspase-3 (CASP3) OTIJRBE7 CASP3_HUMAN Gene/Protein Processing [10]
Molecular Interaction Atlas (MIA) Jump to Detail Molecular Interaction Atlas of This Drug

Drug-Drug Interaction (DDI) Information of This Drug

Coadministration of a Drug Treating the Disease Different from Trovafloxacin (Comorbidity)
DDI Drug Name DDI Drug ID Severity Mechanism Comorbidity REF
Remdesivir DMBFZ6L Moderate Increased risk of hepatotoxicity by the combination of Trovafloxacin and Remdesivir. 1D6YCoronavirus Disease 2019 [1D6YCoronavirus Disease 2019] [11]
Tretinoin DM49DUI Minor Decreased absorption of Trovafloxacin due to intestinal mucosa variation caused by Tretinoin. Acne vulgaris [ED80] [12]
Uracil mustard DMHL7OB Minor Decreased absorption of Trovafloxacin due to intestinal mucosa variation caused by Uracil mustard. Acute myeloid leukaemia [2A60] [12]
Idarubicin DMM0XGL Minor Decreased absorption of Trovafloxacin due to intestinal mucosa variation caused by Idarubicin. Acute myeloid leukaemia [2A60] [12]
Daunorubicin DMQUSBT Minor Decreased absorption of Trovafloxacin due to intestinal mucosa variation caused by Daunorubicin. Acute myeloid leukaemia [2A60] [12]
Bedaquiline DM3906J Moderate Increased risk of hepatotoxicity by the combination of Trovafloxacin and Bedaquiline. Antimicrobial drug resistance [MG50-MG52] [13]
Pexidartinib DMS2J0Z Major Increased risk of hepatotoxicity by the combination of Trovafloxacin and Pexidartinib. Bone/articular cartilage neoplasm [2F7B] [14]
Temozolomide DMKECZD Minor Decreased absorption of Trovafloxacin due to intestinal mucosa variation caused by Temozolomide. Brain cancer [2A00] [12]
Lomustine DMMWSUL Minor Decreased absorption of Trovafloxacin due to intestinal mucosa variation caused by Lomustine. Brain cancer [2A00] [12]
Thiotepa DMIZKOP Minor Decreased absorption of Trovafloxacin due to intestinal mucosa variation caused by Thiotepa. Breast cancer [2C60-2C6Y] [12]
Phenylbutazone DMAYL0T Moderate Additive CNS stimulant effects by the combination of Trovafloxacin and Phenylbutazone. Chronic pain [MG30] [15]
Ketoprofen DMRKXPT Moderate Additive CNS depression effects by the combination of Trovafloxacin and Ketoprofen. Chronic pain [MG30] [16]
Irinotecan DMP6SC2 Minor Decreased absorption of Trovafloxacin due to intestinal mucosa variation caused by Irinotecan. Colorectal cancer [2B91] [12]
Capecitabine DMTS85L Minor Decreased absorption of Trovafloxacin due to intestinal mucosa variation caused by Capecitabine. Colorectal cancer [2B91] [12]
Mestranol DMG3F94 Moderate Decreased absorption of Trovafloxacin due to formation of complexes caused by Mestranol. Contraceptive management [QA21] [17]
Mycophenolic acid DMRBMAU Moderate Altered absorption of Trovafloxacin due to GI flora changes caused by Mycophenolic acid. Crohn disease [DD70] [18]
Cannabidiol DM0659E Moderate Increased risk of hepatotoxicity by the combination of Trovafloxacin and Cannabidiol. Epileptic encephalopathy [8A62] [19]
Mefenamic acid DMK7HFI Moderate Additive CNS stimulant effects by the combination of Trovafloxacin and Mefenamic acid. Female pelvic pain [GA34] [16]
Procarbazine DMIK367 Minor Decreased absorption of Trovafloxacin due to intestinal mucosa variation caused by Procarbazine. Hodgkin lymphoma [2B30] [12]
Brentuximab vedotin DMWLC57 Moderate Increased risk of hepatotoxicity by the combination of Trovafloxacin and Brentuximab vedotin. Hodgkin lymphoma [2B30] [20]
Didanosine DMI2QPE Moderate Decreased absorption of Trovafloxacin due to formation of complexes caused by Didanosine. Human immunodeficiency virus disease [1C60-1C62] [21]
Mipomersen DMGSRN1 Major Increased risk of hepatotoxicity by the combination of Trovafloxacin and Mipomersen. Hyper-lipoproteinaemia [5C80] [22]
Teriflunomide DMQ2FKJ Major Increased risk of hepatotoxicity by the combination of Trovafloxacin and Teriflunomide. Hyper-lipoproteinaemia [5C80] [23]
BMS-201038 DMQTAGO Major Increased risk of hepatotoxicity by the combination of Trovafloxacin and BMS-201038. Hyper-lipoproteinaemia [5C80] [24]
Fludrocortisone DMUDIR8 Major Increased risk of tendinitis/tendon rupture by the combination of Trovafloxacin and Fludrocortisone. Hypo-osmolality/hyponatraemia [5C72] [25]
Meclofenamic acid DM05FXR Moderate Additive CNS stimulant effects by the combination of Trovafloxacin and Meclofenamic acid. Inflammatory spondyloarthritis [FA92] [26]
Iron DMAP8MV Moderate Decreased absorption of Trovafloxacin due to formation of complexes caused by Iron. Iron deficiency anaemia [3A00] [27]
Polyethylene glycol DM4I1JP Moderate Increased risk of lowers seizure threshold by the combination of Trovafloxacin and Polyethylene glycol. Irritable bowel syndrome [DD91] [28]
Lurbinectedin DMEFRTZ Minor Decreased absorption of Trovafloxacin due to intestinal mucosa variation caused by Lurbinectedin. Lung cancer [2C25] [12]
Calaspargase pegol DMQZBXI Moderate Increased risk of hepatotoxicity by the combination of Trovafloxacin and Calaspargase pegol. Malignant haematopoietic neoplasm [2B33] [29]
Fludarabine DMVRLT7 Minor Decreased absorption of Trovafloxacin due to intestinal mucosa variation caused by Fludarabine. Malignant haematopoietic neoplasm [2B33] [12]
Idelalisib DM602WT Moderate Increased risk of hepatotoxicity by the combination of Trovafloxacin and Idelalisib. Mature B-cell leukaemia [2A82] [30]
Mercaptopurine DMTM2IK Minor Decreased absorption of Trovafloxacin due to intestinal mucosa variation caused by Mercaptopurine. Mature B-cell lymphoma [2A85] [12]
Cytarabine DMZD5QR Minor Decreased absorption of Trovafloxacin due to intestinal mucosa variation caused by Cytarabine. Mature B-cell lymphoma [2A85] [12]
Mechlorethamine DM0CVXA Minor Decreased absorption of Trovafloxacin due to intestinal mucosa variation caused by Mechlorethamine. Mature T-cell lymphoma [2A90] [12]
Dacarbazine DMNPZL4 Minor Decreased absorption of Trovafloxacin due to intestinal mucosa variation caused by Dacarbazine. Melanoma [2C30] [12]
Ethinyl estradiol DMODJ40 Moderate Decreased absorption of Trovafloxacin due to formation of complexes caused by Ethinyl estradiol. Menopausal disorder [GA30] [17]
Lanthanum carbonate DMMJQSH Moderate Decreased absorption of Trovafloxacin due to formation of complexes caused by Lanthanum carbonate. Mineral absorption/transport disorder [5C64] [23]
Melphalan DMOLNHF Minor Decreased absorption of Trovafloxacin due to intestinal mucosa variation caused by Melphalan. Multiple myeloma [2A83] [12]
Melphalan flufenamide DMWF5R4 Minor Decreased absorption of Trovafloxacin due to intestinal mucosa variation caused by Melphalan flufenamide. Multiple myeloma [2A83] [12]
Hydroxyurea DMOQVU9 Minor Decreased absorption of Trovafloxacin due to intestinal mucosa variation caused by Hydroxyurea. Myeloproliferative neoplasm [2A20] [12]
Busulfan DMXYJ9C Minor Decreased absorption of Trovafloxacin due to intestinal mucosa variation caused by Busulfan. Myeloproliferative neoplasm [2A20] [12]
Bupropion DM5PCS7 Major Increased risk of lowers seizure threshold by the combination of Trovafloxacin and Bupropion. Nicotine use disorder [6C4A] [31]
Naproxen DMZ5RGV Moderate Additive CNS stimulant effects by the combination of Trovafloxacin and Naproxen. Osteoarthritis [FA00-FA05] [16]
Carboplatin DMG281S Minor Decreased absorption of Trovafloxacin due to intestinal mucosa variation caused by Carboplatin. Ovarian cancer [2C73] [12]
Topotecan DMP6G8T Minor Decreased absorption of Trovafloxacin due to intestinal mucosa variation caused by Topotecan. Ovarian cancer [2C73] [12]
Aspirin DM672AH Moderate Additive CNS stimulant effects by the combination of Trovafloxacin and Aspirin. Pain [MG30-MG3Z] [15]
Etodolac DM6WJO9 Moderate Additive CNS depression effects by the combination of Trovafloxacin and Etodolac. Pain [MG30-MG3Z] [16]
Diflunisal DM7EN8I Moderate Additive CNS depression effects by the combination of Trovafloxacin and Diflunisal. Pain [MG30-MG3Z] [16]
Ibuprofen DM8VCBE Moderate Additive CNS depression effects by the combination of Trovafloxacin and Ibuprofen. Pain [MG30-MG3Z] [16]
Choline salicylate DM8P137 Moderate Additive CNS stimulant effects by the combination of Trovafloxacin and Choline salicylate. Postoperative inflammation [1A00-CA43] [15]
Hydrocortisone DMGEMB7 Major Increased risk of tendinitis/tendon rupture by the combination of Trovafloxacin and Hydrocortisone. Postoperative inflammation [1A00-CA43] [25]
Bromfenac DMKB79O Moderate Additive CNS stimulant effects by the combination of Trovafloxacin and Bromfenac. Postoperative inflammation [1A00-CA43] [15]
Salsalate DM13P4C Moderate Additive CNS stimulant effects by the combination of Trovafloxacin and Salsalate. Rheumatoid arthritis [FA20] [16]
Meloxicam DM2AR7L Moderate Additive CNS stimulant effects by the combination of Trovafloxacin and Meloxicam. Rheumatoid arthritis [FA20] [16]
Oxaprozin DM9UB0P Moderate Additive CNS stimulant effects by the combination of Trovafloxacin and Oxaprozin. Rheumatoid arthritis [FA20] [16]
Flurbiprofen DMGN4BY Moderate Additive CNS depression effects by the combination of Trovafloxacin and Flurbiprofen. Rheumatoid arthritis [FA20] [16]
Dexamethasone DMMWZET Major Increased risk of tendinitis/tendon rupture by the combination of Trovafloxacin and Dexamethasone. Rheumatoid arthritis [FA20] [25]
Leflunomide DMR8ONJ Major Increased risk of hepatotoxicity by the combination of Trovafloxacin and Leflunomide. Rheumatoid arthritis [FA20] [23]
Salicyclic acid DM2F8XZ Moderate Additive CNS stimulant effects by the combination of Trovafloxacin and Salicyclic acid. Seborrhoeic dermatitis [EA81] [15]
Dactinomycin DM2YGNW Minor Decreased absorption of Trovafloxacin due to intestinal mucosa variation caused by Dactinomycin. Solid tumour/cancer [2A00-2F9Z] [12]
Methylprednisolone DM4BDON Major Increased risk of tendinitis/tendon rupture by the combination of Trovafloxacin and Methylprednisolone. Solid tumour/cancer [2A00-2F9Z] [25]
Ifosfamide DMCT3I8 Minor Decreased absorption of Trovafloxacin due to intestinal mucosa variation caused by Ifosfamide. Solid tumour/cancer [2A00-2F9Z] [12]
Docetaxel DMDI269 Minor Decreased absorption of Trovafloxacin due to intestinal mucosa variation caused by Docetaxel. Solid tumour/cancer [2A00-2F9Z] [12]
Trabectedin DMG3Y89 Moderate Increased risk of hepatotoxicity by the combination of Trovafloxacin and Trabectedin. Solid tumour/cancer [2A00-2F9Z] [19]
Mitoxantrone DMM39BF Minor Decreased absorption of Trovafloxacin due to intestinal mucosa variation caused by Mitoxantrone. Solid tumour/cancer [2A00-2F9Z] [12]
Etoposide DMNH3PG Minor Decreased absorption of Trovafloxacin due to intestinal mucosa variation caused by Etoposide. Solid tumour/cancer [2A00-2F9Z] [12]
Prednisolone DMQ8FR2 Major Increased risk of tendinitis/tendon rupture by the combination of Trovafloxacin and Prednisolone. Solid tumour/cancer [2A00-2F9Z] [25]
Taxol DMUOT9V Minor Decreased absorption of Trovafloxacin due to intestinal mucosa variation caused by Taxol. Solid tumour/cancer [2A00-2F9Z] [12]
Doxorubicin DMVP5YE Minor Decreased absorption of Trovafloxacin due to intestinal mucosa variation caused by Doxorubicin. Solid tumour/cancer [2A00-2F9Z] [12]
Naltrexone DMUL45H Moderate Increased risk of hepatotoxicity by the combination of Trovafloxacin and Naltrexone. Substance abuse [6C40] [32]
Plicamycin DM7C8YV Minor Decreased absorption of Trovafloxacin due to intestinal mucosa variation caused by Plicamycin. Testicular cancer [2C80] [12]
Mycophenolate mofetil DMPQAGE Moderate Altered absorption of Trovafloxacin due to GI flora changes caused by Mycophenolate mofetil. Transplant rejection [NE84] [18]
⏷ Show the Full List of 73 DDI Information of This Drug

References

1 Trovafloxacin FDA Label
2 FDA Approved Drug Products from FDA Official Website. 2009. Application Number: (NDA) 050762.
3 BDDCS predictions, self-correcting aspects of BDDCS assignments, BDDCS assignment corrections, and classification for more than 175 additional drugs
4 Critical Evaluation of Human Oral Bioavailability for Pharmaceutical Drugs by Using Various Cheminformatics Approaches
5 Trend Analysis of a Database of Intravenous Pharmacokinetic Parameters in Humans for 1352 Drug Compounds
6 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
7 Cell-based high-throughput screening for aromatase inhibitors in the Tox21 10K library. Toxicol Sci. 2015 Oct;147(2):446-57.
8 TNF enhances trovafloxacin-induced in vitro hepatotoxicity by inhibiting protective autophagy. Toxicol Lett. 2021 May 15;342:73-84. doi: 10.1016/j.toxlet.2021.02.009. Epub 2021 Feb 17.
9 The hepatotoxic fluoroquinolone trovafloxacin disturbs TNF- and LPS-induced p65 nuclear translocation in vivo and in vitro. Toxicol Appl Pharmacol. 2020 Mar 15;391:114915. doi: 10.1016/j.taap.2020.114915. Epub 2020 Feb 6.
10 Pro-inflammatory cytokines enhance dilatation of bile canaliculi caused by cholestatic antibiotics. Toxicol In Vitro. 2019 Aug;58:51-59. doi: 10.1016/j.tiv.2019.03.015. Epub 2019 Mar 12.
11 Cerner Multum, Inc. "Australian Product Information.".
12 Johnson EJ, MacGowan AP, Potter MN, et al "Reduced absorption of oral ciprofloxacin after chemotherapy for haematological malignancy." J Antimicrob Chemother 25 (1990): 837-42. [PMID: 2373666]
13 Product Information. Sirturo (bedaquiline). Janssen Pharmaceuticals, Titusville, NJ.
14 Product Information. Turalio (pexidartinib). Daiichi Sankyo, Inc., Parsippany, NJ.
15 Davey PG "Overview of drug interactions with the quinolones." J Antimicrob Chemother 22(suppl c) (1988): 97-107. [PMID: 3053579]
16 Product Information. Factive (gemifloxacin). GeneSoft Inc, San Francisco, CA.
17 Friedman CI, Huneke AL, Kim MH, Powell J "The effect of ampicillin on oral contraceptive effectiveness." Obstet Gynecol 55 (1980): 33-7. [PMID: 7188714]
18 Product Information. CellCept (mycophenolate mofetil). Roche Laboratories, Nutley, NJ.
19 Cerner Multum, Inc. "UK Summary of Product Characteristics.".
20 Product Information. Adcetris (brentuximab vedotin). Seattle Genetics Inc, Bothell, WA.
21 Knupp CA, Barbhaiya RH "A multiple-dose pharmacokinetic interaction study between didanosine (videx(r)) and ciprofloxacin (cipro(r)) in male subjects seropositive for HIV but asymptomatic." Biopharm Drug Dispos 18 (1997): 65-77. [PMID: 9008270]
22 Product Information. Kynamro (mipomersen). Genzyme Corporation, Cambridge, MA.
23 Canadian Pharmacists Association.
24 Product Information. Juxtapid (lomitapide). Aegerion Pharmaceuticals Inc, Cambridge, MA.
25 FDA. U.S. Food and Drug Administration "Information for Healthcare Professionals. Fluoroquinolone Antimicrobial Drugs. FDA Alert [7/8/2008].".
26 Product Information. Avelox (moxifloxacin) Bayer, West Haven, CT.
27 Nix DE, Wilton JH, Ronald B, Distlerath L, Williams VC, Norman A "Inhibition of norfloxacin absorption by antacids." Antimicrob Agents Chemother 34 (1990): 432-5. [PMID: 2334155]
28 Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates). Braintree Laboratories, Braintree, MA.
29 Al-Nawakil C, Willems L, Mauprivez C, et.al "Successful treatment of l-asparaginase-induced severe acute hepatotoxicity using mitochondrial cofactors." Leuk Lymphoma 55 (2014): 1670-4. [PMID: 24090500]
30 Product Information. Zydelig (idelalisib). Gilead Sciences, Foster City, CA.
31 Product Information. Wellbutrin XL (buPROPion). GlaxoSmithKline, Philadelphia, PA.
32 Product Information. ReVia (naltrexone). DuPont Pharmaceuticals, Wilmington, DE.